Heron Therapeutics, Inc. — Q1 2016 Form 10-Q Summary
Business context and reporting period
Heron Therapeutics is a pre-commercial biotechnology company developing medicines for cancer-related nausea and vomiting and post-operative pain using its Biochronomer drug-delivery technology. The filing covers the unaudited three months ended March 31, 2016, with comparative results for the three months ended March 31, 2015.
- SUSTOL: NDA review remained pending with the FDA. The FDA had delayed the review in January, February and April 2016; on April 18, 2016, the FDA indicated that no substantive deficiencies had been identified and that labeling discussions had begun.
- HTX-019: The company intended to file an NDA in the second half of 2016 under the 505(b)(2) pathway.
- HTX-011: A new Phase 2 dose-finding study in bunionectomy patients began in April 2016, alongside ongoing studies in inguinal hernia repair and abdominoplasty.
Financial metrics
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Revenue | No material product revenue reported | No material product revenue reported | Pre-commercial |
| Research and development expense | $16.1 million | $14.5 million | Up $1.6 million |
| General and administrative expense | $5.4 million | $3.6 million | Up $1.8 million |
| Sales and marketing expense | $11.9 million | $2.3 million | Up $9.6 million |
| Total operating expenses | $33.3 million | $20.4 million | Up $13.0 million |
| Loss from operations | $(33.3) million | $(20.4) million | Loss widened |
| Net loss | $(33.4) million | $(20.6) million | Loss widened $12.9 million |
| Basic and diluted loss per share | $(0.92) | $(0.70) | More unfavorable |
| Net cash used in operating activities | $(32.4) million | $(19.7) million | Use increased $12.7 million |
Comprehensive loss was $33.4 million, including a $41,000 unrealized gain on short-term investments. Stock-based compensation expense was $5.4 million versus $2.6 million in the prior-year quarter and increased reported operating expenses while adding back to operating cash flow.
Liquidity, debt and balance sheet
- Cash and cash equivalents were $68.0 million at March 31, 2016, compared with $75.2 million at December 31, 2015.
- Short-term investments were $32.4 million, compared with $56.0 million at year-end 2015. Cash, cash equivalents and short-term investments totaled approximately $100.4 million at March 31, 2016, versus $131.2 million at December 31, 2015.
- Total assets were $111.8 million and stockholders’ equity was $92.7 million at March 31, 2016.
- Accumulated deficit was $446.3 million.
- Convertible notes had $5.754 million of principal outstanding and a carrying value of $2.388 million after debt discount. The notes bear 6% interest, mature in 2021, are secured by substantially all company assets and may be subject to prepayment at the holders’ option.
- If fully converted, the notes would result in issuance of approximately 7.193 million common shares, representing approximately 16.5% dilution based on the filing’s calculation.
- The company reported compliance with all convertible-note covenants as of March 31, 2016.
Material changes versus the prior comparable period
- Operating expenses increased 64%, principally because sales and marketing spending rose to $11.9 million as the company hired and trained a sales force and prepared for a potential SUSTOL launch.
- Research and development expense increased despite a $6.0 million reduction in SUSTOL-related costs following completion of the Phase 3 program in May 2015. The increase reflected higher personnel costs, stock compensation and HTX-011 clinical and manufacturing costs.
- Operating cash use increased to $32.4 million from $19.7 million. The company also capitalized $2.7 million of SUSTOL pre-launch inventory, creating a new inventory balance.
- Investing activities provided $22.7 million, primarily from maturities of short-term investments, compared with $0.3 million of net investing cash use in Q1 2015.
- Financing activities provided $2.5 million from stock-option exercises, compared with $2.9 million in the prior-year quarter.
Guidance, outlook, risks and unusual items
- Management stated that existing working capital was expected to fund operations through 2016, including SUSTOL regulatory activities, HTX-011 Phase 2 studies, the planned HTX-019 NDA filing and, if SUSTOL were approved, significant commercialization investments.
- The company had no current means of generating material operating cash flow and acknowledged that additional capital may be required if development expands, SUSTOL is not approved, or commercialization is less successful than expected.
- Potential future funding sources include equity or debt offerings, collaborations, borrowings, asset arrangements and royalty transactions. Additional equity could dilute existing stockholders, while the convertible-note covenants restrict certain financing and corporate actions.
- The $2.744 million of capitalized SUSTOL pre-launch inventory could require a material write-off if FDA approval is delayed, denied, or requires different manufacturing specifications.
- Key risks include FDA approval and labeling uncertainty for SUSTOL, prior manufacturing deficiencies identified in connection with an earlier Complete Response Letter, dependence on third-party manufacturers and suppliers, clinical-trial execution, reimbursement and market acceptance, competition, intellectual-property protection and the need for additional financing.
- Operating lease obligations totaled $855,000 under the filing’s contractual-obligation table. In April 2016, the company extended its Redwood City lease through May 31, 2019, with annual basic rent escalating from $985,000 to $1.045 million over the stated periods.
- The company reported no legal proceedings, no off-balance-sheet arrangements and effective disclosure controls at March 31, 2016.
Important facts for investors to verify
- Subsequent FDA action on the SUSTOL NDA, including final approval, label scope, post-marketing requirements and any manufacturing-related conditions.
- Whether the company’s approximately $100.4 million of cash and investments was sufficient beyond 2016 without additional financing.
- Progress, cost and results of HTX-011 Phase 2 trials and the timing and contents of the HTX-019 NDA filing.
- The recoverability of $2.7 million of SUSTOL pre-launch inventory if approval or launch is delayed.
- Potential dilution from approximately 7.193 million shares issuable under the convertible notes and outstanding warrants and options.
- Actual commercial launch spending, manufacturing readiness, pricing, reimbursement and market acceptance if SUSTOL is approved.